JP3942400007
© PR Newswire
11.12.2025
45030
LISTED
XJPX
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
News Preview
- Data reflect new insights and precision oncology advancements in portfolio and pipeline -- Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking oral presentation -TOKYO, Dec. 10, 2025 /PRNewswire/ -- Aste...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2025
45030
LISTED
XJPX
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
News Preview
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML -- Findings from the Phase 3 MORPHO trial in the post-transplant maintenance setting and Phase 1/2 VICEROY trial in newly diagnosed disease highlight how treatment timing, sequen...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2025
45030
LISTED
XJPX
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
News Preview
Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause
Preliminary analysis from OPTION-VMS observational study demonstrated fezolinetant leads to statistically significan...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
22.10.2025
45030
LISTED
XJPX
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
News Preview
Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in cisplatin-ineligible patients with muscle-invasive bladder cancer...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
20.10.2025
45030
LISTED
XJPX
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
News Preview
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area
Study results found no new safety signals and no cases of retinal vasculitis or occlu...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2025
45030
LISTED
XJPX
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
News Preview
TOKYO, Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be featured in six Astellas-s...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2025
45030
LISTED
XJPX
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
News Preview
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression
TOKYO, Oct. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: N...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
45030
LISTED
XJPX
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
News Preview
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -
- Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer se...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2025
45030
LISTED
XJPX
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Compani
News Preview
- Supporting Korean Startups' Drug Discovery Research and Global Expansion -
- First Pharmaceutical Company from Japan to Actively Support the Operation of the Program -
TOKYO, July 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has agreed on a memorandum of understa...
Themefolio
Profiler
Peergroup
© PR Newswire
13.06.2025
45030
LISTED
XJPX
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
News Preview
Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan
TOKYO, June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") today announced that they have agreed on a memorandum of understanding to provide drug-discovery startups in Japan with support in their efforts to go...
Themefolio
Profiler
Peergroup
© PR Newswire
30.05.2025
45030
LISTED
XJPX
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
News Preview
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 -
- XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors, including gastric cancer, gastroesophageal cancer and pancreatic c...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
45030
LISTED
XJPX
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
News Preview
Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy organizations
NORTHBROOK, Ill., May 28, 2025 /PRNewswire/ -- Astellas Patient Centricity is pleased to announce the second annual Patient Advocacy Organizati...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
21.05.2025
45030
LISTED
XJPX
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
News Preview
Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their research endeavorsAward helps biotech startups accelerate early research effortsNORTHBROOK, Ill., May 21, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc....
Themefolio
Profiler
Peergroup
© PR Newswire
19.05.2025
45030
LISTED
XJPX
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
News Preview
16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio
TOKYO, May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical On...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
45030
LISTED
XJPX
Notice of Nominees for Directors
News Preview
TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that during a meeting of its Board of Directors held today, it decided a change in Directors as outlined below. The appointment of Andreas Busch and Mark Enyedy as new candidates to be proposed at the 20th Term Annual...
Themefolio
Profiler
Peergroup
© PR Newswire
01.05.2025
45030
LISTED
XJPX
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
News Preview
ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAY™ (avacincaptad pegol intravitreal solution) pivotal studies
TOKYO, May 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), maker of IZERVAY™ (avacincaptad pegol intravitrea...
Themefolio
Profiler
Peergroup
© PR Newswire
06.03.2025
45030
LISTED
XJPX
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
News Preview
- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions -
TOKYO, March 5, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa,...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
45030
LISTED
XJPX
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
News Preview
Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their researchAward helps biotech start-ups accelerate early drug discovery and research effortsNORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and...
Themefolio
Profiler
Peergroup
© PR Newswire
13.02.2025
45030
LISTED
XJPX
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
News Preview
IZERVAY dosing approved beyond 12 months
TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geogra...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
45030
LISTED
XJPX
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
News Preview
- Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in Japan -
TOKYO, Feb. 5, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission o...
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
45030
LISTED
XJPX
Astellas Makes Announcement about Management Structure
News Preview
TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.
Regarding the Change...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
45030
LISTED
XJPX
China's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
News Preview
- China has the highest number of cases and deaths from gastric cancer of any country worldwide1 -
- Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker expressed by 35% of Chinese patients with advanced gastric and gastroesophageal junction (GEJ) cancer2 -
- Treatment with the claudin 18.2-targeted mo...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
45030
LISTED
XJPX
Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves
News Preview
"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives.
NORTHBROOK, Ill., Dec. 5, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. (TSE: 4503, Head of US Commercial: Michael Petroutsas, "Astellas") today announced the launch of Cooler Moments in partnership with Dr. Jen Ash...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
45030
LISTED
XJPX
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
News Preview
SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, to pilot DIGITIVA™, a non-invasive digital health solution for the management of heart failure patients....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2024
45030
LISTED
XJPX
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
News Preview
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive
TOKYO, Oct. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Admin...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
45030
LISTED
XJPX
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
News Preview
ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS). The EFS wi...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
45030
LISTED
XJPX
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
News Preview
TOKYO, Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be featured in four oral and two poster presentations during the International Menop...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2024
45030
LISTED
XJPX
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
News Preview
Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development
AviadoBio receives $20 million equity investment, up to $30 million in upfront payments and is eligible to receive up to $2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2024
45030
LISTED
XJPX
Japan's Ministry of Health, Labour and Welfare Approves PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
News Preview
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing chemotherapy, the current standard of care for first-line treatment of radically unresectable urothelial carcinoma1
- Approval follows priority review desi...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2024
45030
LISTED
XJPX
Astellas Receives Approval from the European Commission for VYLOY™ (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
News Preview
- Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer1,2
- Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend both progression-free survival and overall survival in...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2024
45030
LISTED
XJPX
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
News Preview
- New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -
TOKYO, Sept. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that DIGITIVA™, a non-invasive digital health solution for h...
Themefolio
Profiler
Peergroup
© PR Newswire
11.09.2024
45030
LISTED
XJPX
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
News Preview
- Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs across a broad range of cancer types -
TOKYO, Sept. 11, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will highlight new data from across its approved...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
45030
LISTED
XJPX
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
News Preview
The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners
TOKYO and CAMBRIDGE, Mass., Sept. 5, 2024 /PRNewswire/ -- Today, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") offic...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
45030
LISTED
XJPX
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
News Preview
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood
- Pooled data from three SKYLIGHT™ studies assess safety and tolerability in Hispanic/Latina women
- Responder analysis from DAYLIGHT™study evaluates reduction in...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
45030
LISTED
XJPX
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
News Preview
- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1
- European Marketing Authorization based on positive overall survival and progression-free survival results from the global Phase 3 EV-302 trial1
TOKYO, Aug. 28, 2024 /PRNewswire/ -- Aste...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
45030
LISTED
XJPX
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
News Preview
HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy
Canadian team has dosed first patient in HIGHLIGHT 1™ Phase 3 study
MARKHAM, ON, Aug. 27, 2024 /CNW/ - Astellas Pharma Inc. (TSE: 4503), President...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
45030
LISTED
XJPX
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
News Preview
- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy -
TOKYO, Aug. 27, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of th...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2024
45030
LISTED
XJPX
China's National Medical Products Administration (NMPA) Approves PADCEV™ (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer
News Preview
- Approval based on the global EV-301 and China EV-203 trials, where enfortumab vedotin significantly improved overall survival (OS) and objective response rate (ORR) respectively in patients following prior treatment with platinum-based chemotherapy and PD-1/L1 inhibitors1,2
- Enfortumab vedotin will provide a much needed new treatment option fo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
